Compare BILL & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILL | LGND |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2019 | 1997 |
| Metric | BILL | LGND |
|---|---|---|
| Price | $49.58 | $292.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | $57.90 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 2.4M | 218.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.07 | ★ 2886.36 |
| EPS | 0.07 | ★ 1.63 |
| Revenue | ★ $1,462,570,000.00 | $141,102,000.00 |
| Revenue This Year | $14.18 | $1.25 |
| Revenue Next Year | $13.83 | $19.41 |
| P/E Ratio | $733.00 | ★ $177.19 |
| Revenue Growth | 13.36 | ★ 29.48 |
| 52 Week Low | $31.41 | $149.51 |
| 52 Week High | $57.21 | $326.63 |
| Indicator | BILL | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 62.32 | 50.08 |
| Support Level | $35.27 | $286.99 |
| Resistance Level | $49.60 | $322.06 |
| Average True Range (ATR) | 2.10 | 11.50 |
| MACD | 0.07 | -1.54 |
| Stochastic Oscillator | 64.80 | 30.49 |
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.